Topic: Agile Operations

Keeping a Close Watch on Clinical Development Trends at DIA

The Health Decisions event team is looking forward to a productive DIA in Washington, DC June 14-18. Vice President, Clinical Affairs Patrick Phillips, D Phil, will lead a forum on project management of adaptive trials and Health Decisions experts will be available through booth #821 to discuss clinical development trends and challenges with sponsors. In… Read more »

New White Paper: Top 10 Clinical Development Trends for 2015

With Q4 2014 upon us, it is time to gear up for 2015. A few things are clear. Clinical development will continue to evolve against a pattern of high-failure rates for products aimed at large populations and higher success rates for targeted therapies. Orphan Drug development will remain an area of intense activity with continued… Read more »

Drug Development: Navigating from Molecule Selection to Market

Life-science VCs are great at vetting molecules and identifying target markets for novel drugs and biologics. If VCs have a weak spot, it is in the area where 80% of novel therapeutics die – clinical development. Like many biotech and pharma executives, VCs tend to think candidate selection largely determines whether new products achieve marketing… Read more »

Risk-Based Monitoring Update: a Message from the RBM Soapbox

As readers of this blog know, Health Decisions embraces risk-based monitoring. Nevertheless, we keep an eye out for issues encountered in the field. A recent post by Nadia Bracken in her RBM Soapbox feature at ClinOpsToolkit raises an important issue sometimes encountered when putting risk-based monitoring into practice. Nadia writes as follows:      Every time I… Read more »

Health Decisions at DIA: LiveTrial Demo, Risk-Based Monitoring and GoPro HERO 3+ Videocam

Vice President Clinical Affairs Dr. Patrick Phillips will lead a Health Decisions team at the DIA 50th Annual Meeting in San Diego June 15 – 19. Patrick looks forward to discussing the essentials and nuances of risk-based monitoring implementations with DIA attendees, as described in this press release. The DIA program lists 13 sessions on… Read more »

White Paper on Biologics Development Available for Download

The current boom in biotech IPOs makes it more important than ever for biologics developers to define safety and efficacy early and chart the proper course to market. As promised in last week’s post, our white paper on meeting the unique challenges of biologics trials is now available for download. Reducing Risk in Biologics Trials:… Read more »